Jakavi
Jakavi (Ruxolitinib 5/20 mg) — Novartis JAK1/JAK2 inhibitor for myelofibrosis, polycythaemia vera (hydroxyurea-resistant/intolerant), graft-versus-host disease.
✓ Medicinsk gennemgået af Morgan Ellis — Apoteksforsker · 8 års erfaring · Sidst gennemgået: maj 2026
Hurtigt svar
Jakavi — Ruxolitinib 5/20 mg (Novartis). JAK1/JAK2 inhibitor for myelofibrosis, polycythaemia vera (hydroxyurea-resistant/intolerant), graft-versus-host disease.
Hvad du får med MedsBase:
- WHO-GMP certificeret producent
- Diskret kuvertemballage uden mærkning
- Levering til hele verden
- Bedømt af 1.400+ kunder (læs anmeldelser)
📦 Genforsendelsesgaranti: hvis din ordre ikke er ankommet inden for 20 hverdage efter afsendelse, genforsender vi den uden ekstra omkostninger. Læs politikken.
Hvorfor bestille fra MedsBase
Jakavi ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor — never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.
⚠️ Specialist-supervised cancer therapy — this medication is started, monitored, and stopped by an oncologist or haematologist. Dosing depends on tumour type, stage, body surface area, organ function, and concomitant therapy. Self-treatment is not appropriate; the information below is educational and supports informed conversations with your specialist.
Tyrosine kinase inhibitors are oral targeted therapies. They require specialist initiation, ongoing therapeutic drug monitoring (where available), and management of class-specific toxicities. Adherence is critical — missed doses risk treatment failure. Most TKIs are CYP3A4 substrates with major drug interactions.
Dose-related anaemia, thrombocytopenia, neutropenia. Increased risk of opportunistic infection (PCP, herpes, TB reactivation, hepatitis B reactivation). Abrupt withdrawal can cause rebound symptoms — taper rather than stop suddenly. Risk of secondary skin cancer.
Ofte stillede spørgsmål
What is a TKI?
Tyrosine kinase inhibitors block specific signalling pathways driving cancer cell growth. Each TKI is selective for different targets (EGFR for gefitinib/erlotinib; multikinase for sorafenib/sunitinib; BCR-ABL for nilotinib/imatinib; BTK for ibrutinib; JAK for ruxolitinib; CDK4/6 for palbociclib).
Bivirkninger?
Class signature: rash (often correlates with response in EGFR inhibitors), diarrhoea, fatigue, hand-foot skin reaction, hypertension (multikinase), hepatotoxicity, QT prolongation. Each TKI has a specific profile.
Lægemiddelinteraktioner?
Most TKIs are CYP3A4 substrates. Strong inhibitors (azoles, macrolides, ritonavir, grapefruit) raise levels and toxicity; strong inducers (rifampicin, phenytoin, carbamazepine, St John’s wort) drop levels and risk treatment failure.
Take with food?
Some TKIs (lapatinib, erlotinib) on empty stomach (food increases bioavailability variably). Others (gefitinib, sorafenib) with or without food. Specific instruction depends on the molecule — confirm with prescribing oncologist.
What about response monitoring?
Imaging (CT/MRI/PET) every 2-3 months early; tumour markers if applicable. Treatment continues while benefit; switch on progression or unacceptable toxicity.
Resistens?
TKI resistance develops over time (typically 9-18 months in solid tumours). Mechanisms: target mutations (T790M for EGFR, T315I for BCR-ABL), alternate pathway activation, target overexpression. Next-generation TKIs (osimertinib, ponatinib) overcome specific resistance mutations.
Hvad hvis jeg glemmer en dosis?
Take when you remember if same day if >6 hours from next dose. Otherwise skip — do not double up. Specific instructions vary by drug; confirm with your oncology team.
Graviditet?
All TKIs are teratogenic — effective contraception during and for at least 4-6 months after for both partners.
Cardiac monitoring?
Multikinase TKIs (sorafenib, sunitinib): BP monitoring, ECG (QT), echocardiogram in selected cases. BCR-ABL TKIs (nilotinib): mandatory ECG at baseline and follow-up — QT prolongation.
Cost-effectiveness?
Generic TKIs are widely manufactured under voluntary licences in India and other jurisdictions. Indian generic prices are dramatically lower than branded equivalents. Quality and bioequivalence are well-documented.
Other Cancer Medications
- Xeloda — capecitabine 500 mg — oral 5-FU prodrug for breast/colorectal/gastric cancers
- Altraz — anastrozole 1 mg — aromatase inhibitor for post-menopausal breast cancer
- Xbira — abiraterone 250 mg — CYP17 inhibitor for metastatic prostate cancer
- Zoldria — zoledronic acid IV — for bone metastases and hypercalcaemia
- Actorise — darbepoetin alfa — for chemotherapy-induced anaemia
More options in Anti Cancer Medication
Rangeret efter seneste MedsBase ordrevolumen — hvad andre kunder i denne kategori vælger.
| Styrke | 5 mg, 20 mg |
|---|---|
| Antal | 28 Kapsel/r, 56 Kapsel/r, 84 Kapsel/r |
| Farmaceutisk form | Tablet/s |
| Producent | Novartis |
| Behandling | Anti Cancer |
| Generisk mærke | Ruxolitinib |
Jakavi
Spørgsmål & svar
Jakavi
Relaterede produkter
Anmeldelser
Der er ingen anmeldelser endnu